The stocks featured in this article have all approached their 52-week highs. When these price levels hit, it typically signals strong business execution, positive market sentiment, or significant industry tailwinds.

One large-cap drugmaker has quietly lapped its peers in 2026 without a single obesity drug in its lineup, while the companies chasing the hottest trend in pharma are fighting for second place and last.

Both Amgen and Repligen saw price target hikes after better-than-expected Q2 results and potential gains from Moderna’s successful Phase 3 trial for melanoma therapy, respectively.

Investors rotated toward profitable drugmakers while personalized cancer-vaccine results energized biotechnology stocks.

Ben Zercher is senior analyst of biotech and pharma at PitchBook Obesity drugs offered the holy grail of drug development: a massive market, biology that works, and a proven blueprint paved by blockbuster GLP-1s. But the gold rush led by Big Pharma and investors has ended. The market is punishing developers whose drugs fail to stand out, and pipelines are being trimmed. Pfizer just axed another program from its massive Metsera deal, while peers like Amgen have begun trimming their own early-stag

Kailera Therapeutics raised one of the biggest obesity biotech IPOs in recent memory, then watched its stock drop nearly 30%. Now several of the world's largest drugmakers have a compelling reason to make a move before pivotal trial data arrives.

President Trump is asking cybersecurity and tech companies to take on a potentially dangerous new role attacking foreign cybercriminals, but the plan offers few incentives to balance the risks. Genetic testing lab Baylor Genetics disclosed a cyber incident where a hacker had access to certain internal systems between June 11 and June 17. An unspecified number of patients had their medical testing and lab results compromised while current and former employees had their Social Security numbers and financial account data exposed, Baylor said.

The market seems to have its pharma giants ranked in a peculiar order, leaving one of the group's fastest-growing performers trading at a middle-of-the-pack multiple rather than the group high.

This top dividend ETF is still a reliable long-term income investment.

By Karen Roman Fulcrum Therapeutics, Inc. (Nasdaq: FULC) said it is merging with Slate Medicines, Inc. to advance next-generation therapeutics to treat migraine and other headache disorders, with the combining company operating as Slate Medicines, Inc. and trading on Nasdaq under the ticker “SLTE.” Slate reported it secured an oversubscribed concurrent private placement of $245 […] The post Fulcrum Therapeutics & Slate Medicines Merge for Next-Generation Migraine Therapies appeared first on Exec

They are fairly risky, but their potential upside is massive.

Most dividend investors chase yield and end up watching their payouts shrink or disappear. These five stocks flip that script by pairing decades of uninterrupted payments with the cash flow coverage to keep them growing.

They are way more than just GLP-1 stocks.

Picture three students turning in exams on the same day, covering the same material. Two walk away with high marks. The third has been raising his grades all semester, yet still gets flagged for summer school. That is roughly the dynamic inside the BofA research note on biotech I received on the ...

Amgen stock has delivered strong gains over the past five years, yet the current share price sits at a discount to an intrinsic value estimate based on a Discounted Cash Flow (DCF) model, while broader valuation checks point to a more mixed picture. Amgen has returned 116.3% over the past five years, which puts more weight on whether the current valuation still leaves room for an attractive long term outcome. Plans to open a new Science and Innovation Center in Hyderabad can support...